Immutep Announces Breakthrough Results in Soft Tissue Sarcoma Trial

Immutep ( (IMMP) ) has provided an update.

Immutep Limited announced positive results from its EFTISARC-NEO Phase II trial, which evaluated the use of eftilagimod alfa (efti) in combination with radiotherapy and KEYTRUDA® for treating resectable soft tissue sarcoma (STS). The trial, presented at the 2025 European Society of Medical Oncology Congress, demonstrated a significant improvement in tumor hyalinization/fibrosis, achieving a median of 51.5% compared to 15% from standard radiotherapy alone. This outcome suggests potential for better patient outcomes, addressing the high unmet medical need in STS treatment.

The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.

Spark’s Take on IMMP Stock

According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.

Immutep’s overall stock score is primarily influenced by its challenging financial performance, marked by persistent losses and negative cash flows. The technical analysis provides some positive momentum, but the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not impact the score.

To see Spark’s full report on IMMP stock, click here.

More about Immutep

Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to leverage this expertise to create innovative treatment options and maximize shareholder value.

Average Trading Volume: 116,588

Technical Sentiment Signal: Buy

Current Market Cap: $278M

For detailed information about IMMP stock, go to TipRanks’ Stock Analysis page.